Picture of Benchmark Holdings logo

BMK — Benchmark Holdings News Story

0.000.00%
gb flag iconLast trade - 00:00
Consumer DefensivesAdventurousSmall CapNeutral

Strategic Review and Formal Sale Process

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240122:nRSV3736Aa&default-theme=true

RNS Number : 3736A  Benchmark Holdings PLC  22 January 2024

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.

 

THIS IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE
2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO
CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER
MIGHT BE MADE.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.

 FOR IMMEDIATE RELEASE   22 January 2024

 

Benchmark Holdings plc

 

Strategic Review, Formal Sale Process and Commencement of Offer Period

 

Benchmark Holdings plc ("Benchmark" or the "Company"), is a market leading
aquaculture genetics, nutrition, and health business, delivering advanced
biotechnology products and solutions that enable the aquaculture industry to
improve its productivity and sustainability, helping address the need for
sustainable aquatic food to feed a growing global population.

 

The Company is a supplier of choice for aquaculture producers worldwide with
market leading positions in genetics, early-stage nutrition and sea lice
solutions and well invested infrastructure to support growth.  The Company's
specialised mission critical products and solutions reflect decades of
invested capital, IP and expertise, which the Board believes are very
difficult to replicate.

 

The Company's genetics strategy is innovation-led, employing a world-leading
team of geneticists who apply the latest technologies on the Company's four
breeding programmes to deliver continuous genetic improvement in growth and
disease resistance.  In nutrition, through INVE, Benchmark delivers advanced
nutrition solutions focused on the early stages of shrimp and marine fish
production, which require specialist nutrition protocols and technical
support, translating into attractive margins.  The health business area
addresses sea lice, one of the largest sustainability challenges for salmon
farmers globally, through veterinary medicinal treatments.

 

Management actions over the last three years have delivered substantial
revenue growth and improvement in profitability and cash conversion.  Since
FY20, Benchmark's revenue from continuing operations has grown from £105.4m
to £169.5m in FY23 and Adjusted EBITDA has increased from £15.5m to £35.5m.
 The Company is well positioned with a strong balance sheet and significant
headroom to grow within its existing markets, as well as multiple potential
avenues for expansion.

 

For the full year ended 30 September 2023, Benchmark delivered 7% revenue
growth(1), 15% increase in adjusted EBITDA(1) and improved its operational
cash conversion from 35% to 58%, demonstrating  continued progress in the
year despite challenging conditions in the shrimp sector, one of the Company's
core markets.

 

The Board believes that the current share price materially undervalues the
combined value of Benchmark's businesses and the long-term prospects of the
Company, which may at least in part be due to the tightly held and illiquid
nature of its ordinary shares.

 

As a result, having consulted with the Company's major shareholders, the Board
has unanimously decided to undertake a formal review of the Company's
strategic options (the "Strategic Review") including, but not limited to, a
sale of the Company as a whole or alternatively the potential sale of one or
more individual business units, to establish whether there is a bidder or
bidders prepared to offer a value for the Company or its individual business
units that the Board considers attractive relative to the Board's view of
intrinsic value.

 

In this context, the Company has agreed with the UK Takeover Panel (the
"Panel") that any discussions in relation to an offer for the Company may take
place within the context of a formal sale process (as set out in Note 2 on
Rule 2.6 of the Code) to enable conversations with parties interested in
making such a proposal to take place on a confidential basis.  The Panel has
granted a dispensation from the requirements of Rules 2.4(a), 2.4(b) and
2.6(a) of the Code such that any interested party participating in the formal
sale process will not be required to be publicly identified as a result of
this announcement and will not be subject to the 28 day deadline referred to
in Rule 2.6(a), for so long as they are participating in the formal sale
process.

 

Parties interested in making a proposal should contact Benchmark's financial
advisers, Evercore and Rabobank, using the contact details below.

 

The Company intends to conduct a targeted process and the first phase will
include the provision of an information pack, following which interested
parties will be invited to submit non-binding indicative offers.  As a
condition to participation in the first phase, parties will be required to
enter into a non-disclosure agreement and standstill arrangement with
Benchmark on terms satisfactory to the Board of Benchmark and on the same
terms, in all material respects, as other selected parties.  It is currently
expected that a select number of parties will be invited to participate in a
second phase.  Further announcements regarding timing and procedures for the
formal sale process will be made as appropriate.

 

The Board reserves the right to alter any aspect of the process or to
terminate it at any time and will make further announcements as appropriate.
The Board also reserves the right to reject any approach or terminate
discussions with any interested party or participant at any time.

 

The Company is not currently in any discussions with any potential offeror
relating to an acquisition of the issued and to be issued share capital of the
Company.  Following this announcement, the Company is now considered to be in
an "offer period" as defined in the Code, and the dealing disclosure
requirements summarised below will apply.

 

Shareholders are advised that there can be no certainty that an offer for the
Company will be made or a sale of individual business units undertaken, nor as
to the terms on which any offer or sale will be made.

 

Enquiries:

 

For further information please contact:

 

 Benchmark Holdings plc                                                           Tel: 0114 240 9939
 Ivonne Cantu, Investor Relations
 Evercore (Financial Adviser to Benchmark)                                        Tel: 020 7653 6000
 Simon Elliott, Julian Oakley, Julien Baril, Parul Seth
 Rabobank (Financial Adviser to Benchmark)                                        Tel: +31 30 7122755
 Reinier Henneman, Anders Rasmussen, Hans Pronk, Benny Vossen
 Deutsche Numis (Broker and NOMAD to Benchmark)                                   Tel: 020 7260 1000
 Freddie Barnfield, Duncan Monteith, Sher Shah
 MHP Group (Press Enquiries)                                                      Tel: 020 3128 8004
 Katie Hunt, Reg Hoare                                                            benchmark@mhpgroup.com

ABOUT BENCHMARK

 

Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.

 

Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia, in all the major
aquaculture regions around the world.  Find out more at www.benchmarkplc.com
(http://www.benchmarkplc.com/) .

 

MAR

 

The information contained within this announcement is considered by the
Company to constitute inside information as stipulated under the Market Abuse
Regulation (EU) No. 596/2014 ("MAR"), and the UK version of MAR which is part
of UK domestic law by virtue of the European Union (Withdrawal) Act 2018.
Upon the publication of this announcement via a Regulatory Information Service
and Newspoint, this inside information will be considered to be in the public
domain.

 

PUBLICATION ON WEBSITE

 

A copy of this announcement will be made available at
https://www.benchmarkplc.com/ (https://www.benchmarkplc.com/) no later than
12:00 noon (London time) on 23 January 2024 (being the business day following
the date of this announcement) in accordance with Rule 26.1 of the Code.  The
content of the website referred to in this announcement is not incorporated
into and does not form part of this announcement.

 

RULE 2.9 INFORMATION

 

In accordance with Rule 2.9 of the Code, the Company confirms that, as at
close of business on 19 January 2024, its issued share capital consisted of
739,370,757 ordinary shares of £0.001 each, with ISIN GB00BGHPT808, which
carry voting rights of one vote per share.  The Company does not hold any
ordinary shares in treasury.

 

OTHER NOTICES

 

This announcement is not intended to and does not constitute an offer to buy
or the solicitation of an offer to subscribe for or sell or an invitation to
purchase or subscribe for any securities or the solicitation of any vote in
any jurisdiction.  The release, publication or distribution of this
announcement in whole or in part, directly or indirectly, in, into or from
certain jurisdictions may be restricted by law and therefore persons in such
jurisdictions should inform themselves about and observe such restrictions.

 

Evercore Partners International LLP ("Evercore"), which is authorised and
regulated by the Financial Conduct Authority ("FCA") in the UK, is acting
exclusively as financial adviser to Benchmark and no one else in connection
with the matters described in this announcement and will not be responsible to
anyone other than Benchmark for providing the protections afforded to clients
of Evercore nor for providing advice in connection with the matters referred
to herein.  Neither Evercore nor any of its subsidiaries, branches or
affiliates owes or accepts any duty, liability or responsibility whatsoever
(whether direct or indirect, whether in contract, in tort, under statute or
otherwise) to any person who is not a client of Evercore in connection with
this announcement, any statement contained herein, any offer or otherwise.
Apart from the responsibilities and liabilities, if any, which may be imposed
on Evercore by the Financial Services and Markets Act 2000, or the regulatory
regime established thereunder, or under the regulatory regime of any
jurisdiction where exclusion of liability under the relevant regulatory regime
would be illegal, void or unenforceable, neither Evercore nor any of its
affiliates accepts any responsibility or liability whatsoever for the contents
of this announcement, and no representation, express or implied, is made by
it, or purported to be made on its behalf, in relation to the contents of this
announcement, including its accuracy, completeness or verification of any
other statement made or purported to be made by it, or on its behalf, in
connection with Benchmark or the matters described in this document.  To the
fullest extent permitted by applicable law, Evercore and its affiliates
accordingly disclaim all and any responsibility or liability whether arising
in tort, contract or otherwise (save as referred to above) which they might
otherwise have in respect of this announcement, or any statement contained
herein.

 

Coöperatieve Rabobank U.A., acting through its Corporate Finance Advisory
M&A department, is supervised by the European Central Bank (ECB) and is
acting as exclusive financial adviser to Benchmark and to no other party in
relation to the matters described in this announcement. Coöperatieve Rabobank
U.A. is not responsible or liable to any other person in relation to the
matters described in this announcement and third parties shall have no (direct
or indirect) rights against Coöperatieve Rabobank U.A.

 

DISCLOSURE REQUIREMENTS OF THE CODE

 

Under Rule 8.3(a) of the Code, any person who is interested in 1% or more of
any class of relevant securities of an offeree company or of any securities
exchange offeror (being any offeror other than an offeror in respect of which
it has been announced that its offer is, or is likely to be, solely in cash)
must make an Opening Position Disclosure following the commencement of the
offer period and, if later, following the announcement in which any securities
exchange offeror is first identified.  An Opening Position Disclosure must
contain details of the person's interests and short positions in, and rights
to subscribe for, any relevant securities of each of (i) the offeree company
and (ii) any securities exchange offeror(s).  An Opening Position Disclosure
by a person to whom Rule 8.3(a) applies must be made by no later than 3.30 pm
(London time) on the 10(th) business day following the commencement of the
offer period and, if appropriate, by no later than 3.30 pm (London time) on
the 10(th) business day following the announcement in which any securities
exchange offeror is first identified.  Relevant persons who deal in the
relevant securities of the offeree company or of a securities exchange offeror
prior to the deadline for making an Opening Position Disclosure must instead
make a Dealing Disclosure.

 

Under Rule 8.3(b) of the Code, any person who is, or becomes, interested in 1%
or more of any class of relevant securities of the offeree company or of any
securities exchange offeror must make a Dealing Disclosure if the person deals
in any relevant securities of the offeree company or of any securities
exchange offeror.  A Dealing Disclosure must contain details of the dealing
concerned and of the person's interests and short positions in, and rights to
subscribe for, any relevant securities of each of (i) the offeree company and
(ii) any securities exchange offeror(s), save to the extent that these details
have previously been disclosed under Rule 8.  A Dealing Disclosure by a
person to whom Rule 8.3(b) applies must be made by no later than 3.30 pm
(London time) on the business day following the date of the relevant dealing.

 

If two or more persons act together pursuant to an agreement or understanding,
whether formal or informal, to acquire or control an interest in relevant
securities of an offeree company or a securities exchange offeror, they will
be deemed to be a single person for the purpose of Rule 8.3.

 

Opening Position Disclosures must also be made by the offeree company and by
any offeror and Dealing Disclosures must also be made by the offeree company,
by any offeror and by any persons acting in concert with any of them (see
Rules 8.1, 8.2 and 8.4).

 

Details of the offeree and offeror companies in respect of whose relevant
securities Opening Position Disclosures and Dealing Disclosures must be made
can be found in the Disclosure Table on the Takeover Panel's website at
www.thetakeoverpanel.org.uk (http://www.thetakeoverpanel.org.uk) , including
details of the number of relevant securities in issue, when the offer period
commenced and when any offeror was first identified. You should contact the
Panel's Market Surveillance Unit on +44 (0)20 7638 0129 if you are in any
doubt as to whether you are required to make an Opening Position Disclosure or
a Dealing Disclosure.

(1)Growth from continuing operations (excluding movements in fair value of
biological assets)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCPPURPGUPCUQP

Recent news on Benchmark Holdings

See all news